Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/26/10	1.980 $	-1.00%	1,10,521
09/26/09	2.000 $	+6.38%	46,230
06/26/06	1.880 $	+2.73%	51,557
05/26/05	1.830 $	-4.19%	34,481
04/26/04	1.910 $	+6.53%	16,757

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.980USD

Average target price

15.00USD

Spread / Average Target

+657.58%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 01:30:00 11/03/2026 am IST			5-day change	1st Jan Change
1.980 ^USD	-1.00%		+10.43%	+20.00%

02/12	Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology	CI
02/12	Chemomab Therapeutics announces nebokitug phase 2 spring trial results	RE

Capitalization	1.22Cr 1.05Cr 94.6L 90.57L 1.65Cr 111.94Cr 1.71Cr 11Cr 4.46Cr 54Cr 4.57Cr 4.48Cr 192.14Cr	P/E ratio 2025 *	-24.8x	P/E ratio 2026 *	-9.9x
Enterprise value	1.22Cr 1.05Cr 94.6L 90.57L 1.65Cr 111.94Cr 1.71Cr 11Cr 4.46Cr 54Cr 4.57Cr 4.48Cr 192.14Cr	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	79.48%	Yield 2025 *	-	Yield 2026 *	-

02/12	Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology	CI
02/12	Chemomab Therapeutics announces nebokitug phase 2 spring trial results	RE
20/11	Chemomab Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
20/11	Chemomab Therapeutics announces third quarter 2025 financial results and provides corporate update	RE
06/11	Chemomab announces multiple presentations at AASLD The Liver Meeting 2025 featuring clinical data from the Nebokitug phase 2 trial in Primary Sclerosing Cholangitis	RE
14/25/14	Chemomab Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
01/25/01	Chemomab Therapeutics, Ltd. Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis At Bsg Live'25	CI
11/25/11	Chemomab Therapeutics Ltd. Reports Positive Feedback from Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis	CI
03/25/03	Chemomab Therapeutics Says Nebokitug Awarded New Patent Protections in China, Russia	MT
16/25/16	Oppenheimer Adjusts Chemomab Therapeutics Price Target to $10 From $11, Maintains Outperform Rating	MT
15/25/15	Chemomab Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
05/25/05	Chemomab Therapeutics, Ltd. Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025	CI
28/25/28	Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment	MT

16/25/16	Oppenheimer Adjusts Chemomab Therapeutics Price Target to $10 From $11, Maintains Outperform Rating	MT
15/24/15	Oppenheimer Adjusts Chemomab Therapeutics Price Target to $11 From $13, Maintains Outperform Rating	MT
06/24/06	Oppenheimer Upgrades Chemomab Therapeutics to Outperform	MT
06/23/06	Roth MKM Starts Chemomab Therapeutics at Buy, $7 Price Target	MT
07/23/07	Oppenheimer Downgrades Chemomab Therapeutics to Perform From Outperform, Removes $7 Price Target	MT

Chemomab Therapeutics Ltd. Share Price

Equities

CMMB

US16385C2035

Biotechnology & Medical Research

Valuation: Chemomab Therapeutics Ltd.

Chart: Chemomab Therapeutics Ltd.

Latest news: Chemomab Therapeutics Ltd.

Analysts' recommendations: Chemomab Therapeutics Ltd.

Press Releases: Chemomab Therapeutics Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Chemomab Therapeutics Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

17/02	Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
02/12	Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology	AQ
25/11	Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit	AQ
24/11	Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit	AQ
20/11	Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update	AQ

1 day	-1.00%
1 week	+10.43%
Current month	+6.45%
1 month	+26.92%
3 months	-19.84%
6 months	-33.78%
Current year	+20.00%

1 week	1.75	2.15
1 month	1.35	2.15
Current year	1.35	2.15
1 year	1.35	6.1
3 years	1.35	10.2
5 years	1.35	316
10 years	1.35	316

Manager	Title	Age	Since
Adi Mor CEO	Chief Executive Officer	45	01/06/2023
Sigal Fattal DFI	Director of Finance/CFO	55	01/06/2023
David Weiner CTO	Chief Tech/Sci/R&D Officer	61	03/12/2021

Director	Title	Age	Since
Adi Mor BRD	Director/Board Member	45	22/09/2011
Nissim Darvish CHM	Chairman	61	01/06/2023
Alan Moses BRD	Director/Board Member	78	16/03/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CHEMOMAB THERAPEUTICS LTD.	-1.00%	+10.43%	-61.92%	-66.55%	1.23Cr
ARGENX SE	+1.36%	-0.81%	+20.33%	+97.71%	4.47TCr
WUXI APPTEC CO., LTD.	+3.35%	+0.43%	+51.85%	+17.36%	3.95TCr
INSMED INCORPORATED	+0.50%	-2.14%	+96.87%	+700.06%	3.09TCr
BIONTECH SE	-17.88%	-16.74%	-20.37%	-34.18%	2.56TCr
WUXI BIOLOGICS (CAYMAN) INC.	-0.44%	+3.29%	+51.29%	-27.37%	1.87TCr
GENMAB A/S	+3.74%	+1.33%	+17.58%	-27.37%	1.65TCr
AKESO, INC.	+0.43%	+21.20%	+63.60%	+191.30%	1.22TCr
SUMMIT THERAPEUTICS INC.	+3.88%	+8.07%	-9.23%	+995.97%	1.22TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.44%	+18.33%	+68.22%	-	1.13TCr
Average	-0.65%	+3.46%	+27.82%	+205.21%	2.12TCr
Weighted average by Cap.	-0.70%	+0.24%	+38.32%	+196.16%

	2025 *	2026 *
Net sales	-	-
Net income	-99.88L -85.76L -77.52L -74.23L -1.36Cr -92Cr -1.4Cr -9.13Cr -3.66Cr -44Cr -3.75Cr -3.67Cr -157.46Cr	-2.13Cr -1.83Cr -1.65Cr -1.58Cr -2.89Cr -195.7Cr -2.98Cr -19Cr -7.8Cr -94Cr -8Cr -7.83Cr -335.92Cr
Net Debt	-	-